Navigation Links
New genomics research investigates metastatic childhood cancers
Date:2/22/2011

Vancouver, BC In a project supported by Genome BC, a Vancouver pediatric pathologist at the BC Cancer Agency/University of British Columbia is leading the team that will explore the genomes (DNA) of four of the most challenging childhood cancers known. Dr. Poul Sorensen and his colleagues in the Canadian Pediatric Cancer Genome Consortium hope to find the link between primary and metastatic tumours using revolutionary genomics technology and a highly skilled consortium of scientists and clinicians.

Most cancer deaths are not caused by the primary disease; rather, it is the invasion and spreading of mutated cells to distant sites in the body (metastasized tumours) that tend to give a poor prognosis for the patient. Using next generation sequencing to rapidly scan the DNA of primary tumours, metastatic tumours and normal tissue, Sorensen and his team are discovering fundamental differences between primary and metastatic disease tissue. This knowledge will not only help to determine how to better treat childhood cancers but more importantly give insight into how to prevent tumours from metastasizing to other parts of the body. If the team can determine which genetic mutations cause the disease to spread, then appropriate therapies can hopefully be designed and/or re-directed to prevent metastasis.

"There is little known about metastatic disease in either pediatric or adult cancer," says Sorensen. "Our biggest challenge to improving survival is to understand the biology of metastatic disease and how to target it." If the team can determine all possible genetic mutations and study a cohort of samples, they can identify the common mutations and determine which mutation is in fact driving the spread of disease. The motivation for the project stems from a lack of understanding in the background mutation of tumours from primary to metastatic progression. "It is imperative to understand metastases and this is an area that has not been well researched on a genomic level internationally," Sorensen adds.

The team will focus on medulloblastoma (brain cancer), metastatic osteosarcoma (bone cancer) and two other types of pediatric brain tumours to uncover genetic abnormalities that direct tumour cells to spread or become resistant to treatment. They will examine and directly compare the genetic signature of each of these diseases in primary tumour cells and tumour cells that have metastasized or relapsed. These studies will produce a first-time view of the tumour genomes in these diseases. This insight not only provides immediate potential for improving tailored therapies for children with these lethal cancers, but will enable the future development of new drugs for patients who otherwise have limited options for treatment.

"Genome BC is thrilled to be funding this essential and ground-breaking work. Our hope is that the results from this research will impact not only on childhood cancers but to shed light on the link between primary and metastatic tumours for all cancer patients," says Dr. Alan Winter, President and CEO of Genome BC.

"Having the genetic, biological and clinical expertise in Vancouver makes this an ideal place to lead this research. The research team has access to rare samples and can tap into an international network to allow for a quick and easy liaison from bench to bedside," says Sorensen. The mutational landscape of cancer cells is nearly impossible to find with only one tumour to analyze; however, with a national network and international linkages the team can begin to make the imperative connections between normal and mutated genes across a larger group of cases.

The $2.8 million (CDN) research project is also funded by the Canadian Institutes of Health Research (CIHR), Genome Canada, Genome Quebec and the C17 Research Network.


'/>"/>

Contact: Jennifer Boon
jboon@genomebc.ca
778-327-8374
Genome BC
Source:Eurekalert

Related medicine news :

1. Promise of genomics research needs a realistic view
2. NHGRI charts course for the next phase of genomics research
3. La Jolla Institute to develop San Diegos first center for RNAi genomics research
4. Radiation pharmacogenomics identifies biomarkers that could personalize cancer treatment
5. St. Jude researcher receives grant to focus on cancer pharmacogenomics in children
6. Genentech uses Complete Genomics human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature
7. Lawrence Berkeley National Laboratory and OpenHelixTM Announce an Updated Free Tutorial Suite for VISTA: Tools for Comparative Genomics
8. Compound used to block cholesterol could also kill breast cancer, MU researcher finds
9. Queens University researcher connects cannabis use and sexual dysfunction
10. Research uncovers a secret society connecting through the Internet
11. $1.9 million NIH grant supports research in the most common soft tissue tumor in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
Breaking Medicine Technology: